Citations

Showing 10 of 108162 citations.

Temperature‐corrected proton density fat fraction estimation using chemical shift‐encoded MRI in phantoms
Navaratna, Ruvini , Zhao, Ruiyang , Colgan, Timothy J. , Hu, Peng , Bydder, Mark , Bashir, Mustafa R. , Middleton, Michael S. , Serai, Suraj D. , Chenevert, Thomas L. , Smith, Mark A. , Henderson, Walter C. , Hamilton, Gavin , Shu, Yunhong , Tkach, Jean A. , Brittain, Jean H. , Hu, Houchun Harry , Serai, Suraj D , Shu, Yunhong , Trout, Andrew T , Hernando, Diego , Reeder, Scott B. , Hamilton, Gavin , Yokoo, Takeshi , Malyarenko, Dariya I. , Sirlin, Claude B. , Trout, Andrew T.

Mayo Clinic

Magnetic Resonance in Medicine | February 11, 2021 | Volume: 86 | Issue: 1 | Pages: 69-81

10.1002/mrm.28669 | PMID 33565112 Get It

PurposeChemical shift‐encoded MRI (CSE‐MRI) is well‐established to quantify proton density fat fraction (PDFF) as a quantitative biomarker of hepatic steatosis. However, temperature is known to bias PDFF estimation in phantom studies. In this study, strategies were developed and evaluated to correct for the effects of temperature on PDFF estimation through simulations, temperature‐controlled experiments, and a multi‐center, multi‐vendor phantom study.Theory and MethodsA technical solution that assumes and automatically estimates a uniform, global temperature throughout the phantom is proposed. Computer simulations modeled the effect of temperature on PDFF estimation using magnitude‐, complex‐, and hybrid‐based CSE‐MRI methods. Phantom experiments were performed to assess the temperature correction on PDFF estimation at controlled phantom temperatures. To assess the temperature correction method on a larger scale, the proposed method was applied to data acquired as part of a nine‐site multi‐vendor phantom study and compared to temperature‐corrected PDFF estimation using an a priori guess for ambient room temperature.ResultsSimulations and temperature‐controlled experiments show that as temperature deviates further from the assumed temperature, PDFF bias increases. Using the proposed correction method and a reasonable a priori guess for ambient temperature, PDFF bias and variability were reduced using magnitude‐based CSE‐MRI, across MRI systems, field strengths, protocols, and varying phantom temperature. Complex and hybrid methods showed little PDFF bias and variability both before and after correction.ConclusionCorrection for temperature reduces temperature‐related PDFF bias and variability in phantoms across MRI vendors, sites, field strengths, and protocols for magnitude‐based CSE‐MRI, even without a priori information about the temperature.
Retinoblastoma in an older Hispanic child masquerading as pars planitis: A case report
Domínguez‐Varela, Irving Armando , Aguilera-Partida, Jorge A, Dalvin, Lauren A. , Garza‐Garza, Lucas A. , Thompson-García, Leslie M, Barbosa-Quintana, Álvaro, Ancona‐Lezama, David , Dalvin, Lauren A

Mayo Clinic

European Journal of Ophthalmology | February 11, 2021 | Volume: 32 | Issue: 3 | Pages: NP71-NP74

10.1177/1120672121994487 | PMID 33567900 Get It

Introduction: To report a case of a Hispanic girl with late-onset Retinoblastoma (Rb) who was misdiagnosed as a pars planitis prior to referral. Nearly 95% of all Rb cases are detected before age 5, and this patient was 8 years-old. Methods: Case report of a late-onset Retinoblastoma with anterior chamber (AC) involvement plus the presence of an Ahmed valve. The patient had a history of a couple of months of topical therapy comprising medication for glaucoma, systemic steroids, and a filtration surgery (Ahmed valve), after that a biopsy was performed prior to referral. Upon arrival at our clinic, we performed an examination under anesthesia (EUA) and a B-scan ultrasound (US). Results: Unilateral Retinoblastoma with an Ahmed valve in an AC filled with Rb seeds was diagnosed with the EUA and US in the left eye. An orbital exenteration with map biopsies of the left orbital cavity was performed with confirmation by histopathology of a poorly differentiated endophytic retinoblastoma with Bruch’s membrane invasion. Follow-up sessions were then arranged as well as subsequent systemic chemotherapy cycles. Conclusion: Given the rare incidence of retinoblastoma in children older than 5 years old, it can be easily mistaken for other differential diagnoses and treated with filtration surgeries that could put the patient’s life at risk. In this report, late-onset Rb diagnosis is highlighted as a differential diagnosis in children and adults with atypical uveitis, which required a multidisciplinary approach.
Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
Pang, Ran, Zhou, Xin-Yao, Wang, Xiangling, Wang, Bin, Yin, Xue-Lai, Bo, Hai, Jung, Jae Hung, Pang, Ran, Zhou, Xin-Yao, Wang, Xiangling, Wang, Bin, Yin, Xue-Lai, Bo, Hai, Jung, Jae Hung

Mayo Clinic

Cochrane Database of Systematic Reviews | February 11, 2021 | Volume: 2021 | Issue: 2 | Pages: No page available

10.1002/14651858.cd012336.pub2 | PMID 33567116 Get It

Detection of bacterial fluorescence from in vivo wound biofilms using a point‐of‐care fluorescence imaging device
Jones, Laura , Reynolds, Landrye, Diaz, Rachel C., George, Isaiah K., Little, William, Fleming, Derek , D’souza, Anna, Rumbaugh, Kendra P. , Smith, Allie Clinton , Fleming, Derek , López, Andrea J. , Rennie, Monique Y.

Mayo Clinic

International Wound Journal | February 11, 2021 | Volume: 18 | Issue: 5 | Pages: 626-638

10.1111/iwj.13564 | PMID 33565263 Get It

AbstractWound biofilms must be identified to target disruption and bacterial eradication but are challenging to detect with standard clinical assessment. This study tested whether bacterial fluorescence imaging could detect porphyrin‐producing bacteria within a biofilm using well‐established in vivo models. Mouse wounds were inoculated on Day 0 with planktonic bacteria (n = 39, porphyrin‐producing and non‐porphyrin‐producing species, 107 colony forming units (CFU)/wound) or with polymicrobial biofilms (n = 16, 3 biofilms per mouse, each with 1:1:1 parts Staphylococcus aureus/Escherichia coli/Enterobacter cloacae, 107 CFU/biofilm) that were grown in vitro. Mouse wounds inoculated with biofilm underwent fluorescence imaging up to Day 4 or 5. Wounds were then excised and sent for microbiological analysis. Bacteria‐matrix interaction was assessed with scanning electron microscopy (SEM) and histopathology. A total of 48 hours after inoculation with planktonic bacteria or biofilm, red fluorescence was readily detected in wounds; red fluorescence intensified up to Day 4. Red fluorescence from biofilms persisted in excised wound tissue post‐wash. SEM and histopathology confirmed bacteria‐matrix interaction. This pre‐clinical study is the first to demonstrate the fluorescence detection of bacterial biofilm in vivo using a point‐of‐care wound imaging device. These findings have implications for clinicians targeting biofilm and may facilitate improved visualisation and removal of biofilms.
Embracing Genetic Diversity to Improve Black Health
Oni‐Orisan, Akinyemi , Mavura, Yusuph , Banda, Yambazi , Thornton, Timothy A. , Sebro, Ronnie , Oni-Orisan, Akinyemi

Mayo Clinic

New England Journal of Medicine | February 10, 2021 | Volume: 384 | Issue: 12 | Pages: 1163-1167

10.1056/nejmms2031080 | PMID 33567186 Get It

Relationship of motor mechanisms to gastroparesis symptoms: toward individualized treatment
Camilleri, Michael

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | February 10, 2021 | Volume: 320 | Issue: 4 | Pages: G558-G563

10.1152/ajpgi.00006.2021 | PMID 33566731 Get It

Following a classical paper by Dr. Keith A. Kelly published in this journal, and over the past 40 years, there has been increased understanding of the functions of different regions of the stomach, specifically the fundus, antrum, and pylorus. Several of the important physiological principles were based on in vivo animal studies that led to the appreciation of regional function and control mechanisms. These include the roles of the extrinsic parasympathetic vagal innervation, the gastric enteric nervous system and electrical syncytium consisting of pacemaker cells and smooth muscle cells, and duodenogastric reflexes providing feedback regulation following the arrival of food and hydrogen ions stimulating the release of hormones and vagal afferent mechanisms that inhibit gastric motility and stimulate pyloric contractility. Further insights on the role of regional motor functions in gastric emptying were obtained from observations in patients following diverse gastric surgeries or bariatric procedures, including fundoplication, Billroth I and sleeve gastrectomy, and sleeve gastroplasty. Antropyloroduodenal manometry and measurements of pyloric diameter and distensibility index provided important assessments of the role of antral hypomotility and pylorospasm, and these constitute specific targets for individualized treatment of patients with gastroparesis. Moreover, in patients with upper gastrointestinal symptoms suggestive of gastroparesis, the availability of measurements of gastric accommodation and pharmacological agents to reduce gastric sensitivity or enhance gastric accommodation provide additional specific targets for individualized treatment. It is anticipated that, in the future, such physiological measurements will be applied in patients to optimize choice of therapy, possibly including identifying the best candidate for pyloric interventions.
Ligament of Treitz: Anatomy, Relevance of Radiologic Findings, and Radiologic-Pathologic Correlation
Nassar, Sameh , Menias, Christine O. , Palmquist, Sarah , Pickhardt, Perry J. , Gaballah, Ayman H. , Elsayes, Khaled M. , Nada, Ayman , Shaaban, Akram M.

Mayo Clinic

American Journal of Roentgenology | February 10, 2021 | Volume: 216 | Issue: 4 | Pages: 927-934

10.2214/ajr.20.23273 | PMID 33566632 Get It

Second tumor risk in children treated with proton therapy
Indelicato, Daniel J. , Bates, James E. , Vega, Raymond B. Mailhot , Rotondo, Ronny L. , Hoppe, Bradford S. , Morris, Christopher G. , Looi, Wen Shen , Sandler, Eric , Aldana, Philipp R. , Bradley, Julie A. , Hoppe, Bradford S , Indelicato, Daniel J , Mailhot Vega, Raymond B

Mayo Clinic

Pediatric Blood & Cancer | February 10, 2021 | Volume: 68 | Issue: 7 | Pages: No page available

10.1002/pbc.28941 | PMID 33565257 Get It

Abstract Background Out‐of‐field neutron dissemination during double‐scattered proton therapy has raised concerns of increased second malignancies, disproportionally affecting pediatric patients due to the proportion of body exposed to scatter dose and inherent radiosensitivity of developing tissue. We sought to provide empiric data on the incidence of early second tumors. Methods Between 2006 and 2019, 1713 consecutive children underwent double‐scattered proton therapy. Median age at treatment was 9.1 years; 371 were ≤3 years old. Thirty‐seven patients (2.2%) had tumor predisposition syndromes. Median prescription dose was 54 Gy (range 15–75.6). Median follow‐up was 3.3 years (range 0.1–12.8), including 6587 total person‐years. Five hundred forty‐nine patients had ≥5 years of follow‐up. A second tumor was defined as any solid neoplasm throughout the body. Results Eleven patients developed second tumors; the 5‐ and 10‐year cumulative incidences were 0.8% (95% CI, 0.4–1.9%) and 3.1% (95% CI, 1.5–6.2%), respectively. Using age‐ and gender‐specific data from the Surveillance, Epidemiology, and End Results (SEER) program, the standardized incidence ratio was 13.5; the absolute excess risk was 1.5/1000 person‐years. All but one patient who developed second tumors were irradiated at ≤5 years old ( p < .0005). There was also a statistically significant correlation between patients with tumor predisposition syndromes and second tumors ( p < .0001). Excluding patients with tumor predisposition syndromes, 5‐ and 10‐year rates were 0.6% (95% CI, 0.2–1.7%) and 1.7% (95% CI, 0.7–4.0%), respectively, with all five malignant second tumors occurring in the high‐dose region. Conclusion Second tumors are rare within the decade following double‐scattered proton therapy, particularly among children irradiated at >5 years old and those without tumor predisposition syndrome.
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma
Brown, Paul D. , Chung, Caroline , Liu, Diane D. , McAvoy, Sarah , Grosshans, David R. , Mahajan, Anita , McGovern, Susan L. , McAleer, Mary-Fran, Ghia, Amol J. , Sulman, Erik P. , Peñas-Prado, Marta , Heimberger, Amy B. , Guha‐Thakurta, Nandita , Sulman, Erik P , Feghali, Karine A. Al , Li, Jing , McAleer, Mary Frances , Groot, John de , Heimberger, Amy B. , Wang, Jihong , Armstrong, Terri S. , Gilbert, Mark R. , Wefel, Jeffrey S.

Mayo Clinic

Neuro-Oncology | February 10, 2021 | Volume: 23 | Issue: 8 | Pages: 1337-1347

10.1093/neuonc/noab040 | PMID 33647972 Get It

Abstract Background To determine if proton radiotherapy (PT), compared to intensity-modulated radiotherapy (IMRT), delayed time to cognitive failure in patients with newly diagnosed glioblastoma (GBM). Methods Eligible patients were randomized unblinded to PT vs IMRT. The primary endpoint was time to cognitive failure. Secondary endpoints included overall survival (OS), intracranial progression-free survival (PFS), toxicity, and patient-reported outcomes (PROs). Results A total of 90 patients were enrolled and 67 were evaluable with median follow-up of 48.7 months (range 7.1-66.7). There was no significant difference in time to cognitive failure between treatment arms (HR, 0.88; 95% CI, 0.45-1.75; P = .74). PT was associated with a lower rate of fatigue (24% vs 58%, P = .05), but otherwise, there were no significant differences in PROs at 6 months. There was no difference in PFS (HR, 0.74; 95% CI, 0.44-1.23; P = .24) or OS (HR, 0.86; 95% CI, 0.49-1.50; P = .60). However, PT significantly reduced the radiation dose for nearly all structures analyzed. The average number of grade 2 or higher toxicities was significantly higher in patients who received IMRT (mean 1.15, range 0-6) compared to PT (mean 0.35, range 0-3; P = .02). Conclusions In this signal-seeking phase II trial, PT was not associated with a delay in time to cognitive failure but did reduce toxicity and patient-reported fatigue. Larger randomized trials are needed to determine the potential of PT such as dose escalation for GBM and cognitive preservation in patients with lower-grade gliomas with a longer survival time.
Outcomes of Patients with Thrombocytopenia Evaluated at Hematology Subspecialty Clinics
Rahman, Zaid Abdel , Miller, Kevin C. , Jabbour, Hiba , Alkhatib, Yaser , Donthireddy, Vijaya, Rahman, Zaid H. Abdel , Abdel Rahman, Zaid H , Miller, Kevin C

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | February 10, 2021 | Volume: 16 | Issue: 1 | Pages: 35-41

10.1016/j.hemonc.2021.01.002 | PMID 36634282 Get It

Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a common reason for hematology referrals. Workup for thrombocytopenia is not standardized and frequently does not follow an evidence-based algorithm. We conducted a systematic analysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytopenia at hematology clinics in a tertiary referral center between 2013 and 2016. Patient and methods: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period. Patients were followed for 1 year from the initial hematology evaluation and assessed for the development of a hematologic malignancy, rheumatologic, or infectious diseases among other clinical outcomes. Results: We evaluated 472 patients with a median (range) age of 61 (17–94) years. The majority (63.8%) had mild thrombocytopenia. Within 1 year of follow-up, 14 patients (3.0%) were diagnosed with a hematologic malignancy. A higher likelihood of developing a hematologic malignancy was noted in patients with concurrent leukopenia (hazard ratio [HR] 9.97, 95% confidence interval [CI] 3.28–30.32, p < .01) and increasing age (HR per 10-year deciles 1.52, 95% CI 1.03–2.25, p = .03). In patients with asymptomatic isolated mild thrombocytopenia, laboratory testing did not reveal any significant positive findings and patients did not receive any new major diagnosis during the follow-up period. Conclusion: Our findings provide basis and call for development of an evidence-based algorithmic approach for evaluation of patients with thrombocytopenia, testing, and referrals. It also supports a conservative approach mainly driven by physical exam signs, symptoms, and other laboratory findings for patients with isolated mild thrombocytopenia.